Levonorgestrel release rates over 5 years with the Liletta® 52-mg intrauterine system

Contraception

Volumn 94, Issue 4, 2016, Pages 353-356

  Creinin, Mitchell D ^a   Jansen, Rolf ^b   Starr, Robert M ^b   Gobburu, Joga ^c   Gopalakrishnan, Mathangi ^c   Olariu, Andrea ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Medicines360   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Contraception; Intrauterine device; Levonorgestrel; Liletta; Release rate

Indexed keywords

LEVONORGESTREL; CONTRACEPTIVE AGENT; DELAYED RELEASE FORMULATION;

ADOLESCENT; ADULT; ARTICLE; CHRONOPHARMACOLOGY; DRUG RELEASE; DRUG WITHDRAWAL; EX VIVO STUDY; FEMALE; HUMAN; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SECONDARY ANALYSIS; TREATMENT DURATION; UNITED STATES; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; INTRAUTERINE CONTRACEPTIVE DEVICE; MIDDLE AGED; MULTICENTER STUDY; PHARMACOKINETICS; PHASE 3 CLINICAL TRIAL; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 84964852501     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2016.04.010     Document Type: Article

References (12)

1. [1] Andersson, K., Odlind, V., Rybo, G., Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 49 (1994), 56–72.
2. [2] Nelson, A., Apter, D., Hauck, B., Schmelter, T., Rybowski, S., Rosen, K., et al. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol 122 (2013), 1205–1213.
3. [3] Eisenberg, D.L., Schreiber, C.A., Turok, D.K., Teal, S.B., Westhoff, C.L., Creinin, M.D., et al. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. Contraception 92 (2015), 10–16.
4. [4] Lewis, R.A., Taylor, D., Natavio, M.F., Melamed, A., Felix, J., Mishell, D. Jr., Effects of the levonorgestrel-releasing intrauterine system on cervical mucus quality and sperm penetrability. Contraception 82 (2010), 491–496.
5. [5] Bastianelli, C., Farris, M., Rapiti, S., Vecchio, R.B., Benagiano, G., Different bleeding patterns with the use of levonorgestrel intrauterine system: are they associated with changes in uterine artery blood flow?. Biomed Res Int, 2014, 2014, 815127.
6. [6] Medicines360, A study of a levonorgestrel-releasing intrauterine system for long-term, reversible contraception. https://clinicaltrials.gov/ct2/show/NCT00995150?term=medicines360&rank=1 [Accessed February 8, 2016].
7. [7] U.S. Food and Drug Administration, Mirena FDA drug approval package, clinical pharmacology biopharmaceutics review(s). www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-225.pdf_Mirena_BioPharmr.pdf [Accessed January 11, 2016].
8. [8] Mirena package insert: Bayer HealthCare Pharmaceuticals Inc, Mirena prescribing information. 2015.
9. [9] Skyla package insert: Bayer HealthCare Pharmaceuticals Inc., Skyla prescribing information. 2013.
10. [10] World Health Organization Department of Reproductive Health and Research (WHO/RHR), Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP), Knowledge for health project. Family planning: a global handbook for providers (2011 update). 2011, CCP and WHO, Baltimore and Geneva.
11. [11] Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC), U.S. selected practice recommendations for contraceptive use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use., 2nd ed. MMWR Recomm rep, 62(RR-05), 2013, 1–60.
12. [12] Bird, R., Stewart, W., Lightfoot, E., Transport phenomena. 1960, John Wiley & Sons, New York.